Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.51 |
| ▸ | AURKA | O14965 | 6/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | ITK | Q08881 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4001391 | 0.82 | SYK (0.67) | SYKAURKAJAK2AURKBEGFR | |
| SCHEMBL654088 | 0.81 | SYK (0.74) | SYKAURKA | |
| SCHEMBL5026033 | 0.81 | SYK (0.53) | SYKAURKAEGFR | |
| SCHEMBL5029402 | 0.78 | SYK (0.69) | SYKAURKAJAK2AURKBEGFR | |
| SCHEMBL27612501 | 0.78 | SYK (0.51) | SYKAURKAJAK2AURKBEGFR | |
| SCHEMBL5025951 | 0.77 | SYK (0.63) | SYKAURKAJAK2AURKBEGFR | |
| SCHEMBL653164 | 0.77 | SYK (0.51) | SYKAURKAEGFR | |
| SCHEMBL4003224 | 0.77 | SYK (0.47) | SYKAURKAJAK2AURKBEGFR | |
| SCHEMBL27631520 | 0.77 | SYK (0.55) | SYKAURKAJAK2EGFRITK | |
| SCHEMBL655818 | 0.76 | SYK (0.46) | SYKAURKAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904457-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006133426-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |